Poket News

Covaxin shows 77.8% efficacy against 'Delta Variant'


  • Hyderabad-based Bharat Biotech Company limited has claimed that its Covaxin, has shown 77.8% efficacy against COVID-19 during the Phase-3 data. 
  • WHO has recently granted Covaxin the emergency use authorization and the shot has already been cleared for use in as many as 17 nations across the world.
  • Lancet noted that the vaccine made by Bharat Biotech is highly efficacious & presents no safety concern, also inducing a robust antibody response 2 weeks after 2 doses of the shot are administered.